Mini reviewPublished 17 Jun 2024
Translational Research and Clinical Implications of Pharmacogenomics and Pharmacogenetics in Osteosarcoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pharmacogenomics and pharmacogenetics are burgeoning fields that aim to personalize medicine by tailoring drug treatments based on individual genetic profiles. In osteosarcoma, the most common primary malignant bone tumor in children and adolescents, understanding genetic variations that affect drug response can significantly improve therapeutic outcomes. This article explores the translational studies and clinical impacts of pharmacogenomics and pharmacogenetics in osteosarcoma. It delves into the molecular underpinnings of the disease, reviews current literature on genetic markers associated with drug response, and discusses how these findings can be integrated into clinical practice to enhance treatment efficacy and reduce adverse effects. The convergence of genetic research and clinical application holds promise for more effective and individualized treatments for osteosarcoma patients.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cancer Clinical Trials
- SubjectOncology & Cancer
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Alfredo Zubiar”
